{"url_path":"/sec/capr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-060382-index.html","accession_number":"0001104659-26-060382","cik":"0001133869","ticker":"CAPR","issuer_name":"CAPRICOR THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-060382-index.html","primary_entity_key":"0001133869","primary_entity_name":"CAPRICOR THERAPEUTICS, INC."},"word_count":481,"has_tables":true,"body_markdown":"**Item 6.  Exhibits.**\n\n3.1\n\n​\n\n[Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 9, 2007).](https://www.sec.gov/Archives/edgar/data/1133869/000114420407006159/v065143_ex3-1.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n3.2\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 26, 2013).](https://www.sec.gov/Archives/edgar/data/1133869/000114420413064127/v361510_ex3-1.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n3.3\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 4, 2019).](https://www.sec.gov/Archives/edgar/data/1133869/000114420419029669/tv522974_ex3-1.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n3.4\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 15, 2024).](https://www.sec.gov/Archives/edgar/data/1133869/000155837024008313/capr-20240514xex3d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.5\n\n​\n\n[Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on February 9, 2007).](https://www.sec.gov/Archives/edgar/data/1133869/000114420407006159/v065143_ex3-2.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.6\n\n​\n\n[Certificate of Amendment of the Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 25, 2020).](https://www.sec.gov/Archives/edgar/data/1133869/000110465920098381/tm2029227d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n​\n\n[Certification of Principal Executive Officer.*](capr-20260331xex31d1.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n31.2\n\n​\n\n[Certification of Principal Financial Officer.*](capr-20260331xex31d2.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n32.1\n\n​\n\n[Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*](capr-20260331xex32d1.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n32.2\n\n​\n\n[Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*](capr-20260331xex32d2.htm)\n\n​\n\n  ​\n\n​\n\n​\n\n​\n\n101\n\n​\n\nThe following financial information from Capricor Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n​\n\n* Filed herewith.\n\n49\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on May 13, 2026.\n\n \n\n**CAPRICOR THERAPEUTICS, INC.**\n\n \n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Linda Marbán, Ph.D.\n\n \n\n \n\nLinda Marbán, Ph.D.\n\n \n\n \n\nChief Executive Officer\n\n \n\n* *\n\n*(Principal Executive Officer)*\n\n \n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Anthony J. Bergmann\n\n \n\n \n\nAnthony J. Bergmann\n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n*(Principal Financial and Principal Accounting Officer)*\n\n​\n\n​\n\n​\n\n50"}